Axsome's Symbravo Shows Long-Term Benefits in Migraine Disability and Quality of Life
核心洞察
Axsome Therapeutics presented 12-month data from the Phase III MOVEMENT trial showing Symbravo (meloxicam + rizatriptan) improved migraine (搜索) disability scores in 45.1% of patients.
The study demonstrated sustained improvements across multiple quality of life measures, with up to 60.7% of patients achieving meaningful improvements in work and social function domains.
Long-term safety data showed only 1.8% discontinuation rate due to adverse events, supporting Symbravo's tolerability profile over extended use.
Axsome Therapeutics presented compelling long-term efficacy data for Symbravo (meloxicam + rizatriptan) at the 2026 American Academy of Neurology meeting, demonstrating sustained improvements in migraine (搜索)-related disability and quality of life measures over 12 months of treatment. The results from the Phase III MOVEMENT trial provide crucial evidence for the fixed-dose combination therapy's position in the competitive acute migraine market.
Long-Term Disability Improvements
The open-label MOVEMENT trial followed participants who had completed the pivotal MOMENTUM or INTERCEPT trials, continuing treatment with Symbravo for up to 12 months. The study revealed significant improvements in the Migraine (搜索) Disability Assessment (MIDAS) score, with 45.1% of patients achieving a minimal clinically important difference defined as greater than 4.5-point improvement. Given the baseline mean MIDAS score of 22.5, indicating severe disability, these improvements would reduce patient disability from severe to moderate levels.
Headache-Impact Test (HIT-6) scores showed progressive improvement over time, with the percentage of participants reaching meaningful clinical improvement increasing from 21.4% at Month 1 to 34.1% at Month 12. This progressive enhancement suggests cumulative benefits with continued Symbravo use.
Quality of Life Enhancements
The 14-item Migraine (搜索)-Specific Quality of Life Questionnaire (MSQ) demonstrated improvements across all three evaluated domains. The most substantial benefits were observed in functional domains, with 57.8% of patients achieving meaningful improvement in role function-restrictive measures and 60.7% in role function-preventive measures at 12 months. Both domains required greater than five-point changes to meet the minimal clinically important difference threshold.
The emotional function subdomain showed more modest improvements, with 39.3% of patients reaching the eight-point threshold for meaningful clinical improvement at 12 months.
Safety Profile Maintained
The 12-month safety data confirmed Symbravo's tolerability profile established in short-term trials. The treatment-emergent adverse event discontinuation rate remained low at 1.8%, demonstrating sustained tolerability over extended use periods.
Market Positioning Challenges
Symbravo faces significant competition in the acute migraine (搜索) therapy market, competing against seven approved triptans with generic availability, dihydroergotamine mesylate formulations, gepants, and Eli Lilly's Reyvow (lasmiditan). Key opinion leaders have expressed concerns about cost considerations, particularly given that both meloxicam and rizatriptan components are available as separate generics.
The long-term data builds upon previous meta-analysis results presented at AAN 2025, where Symbravo demonstrated superior efficacy in achieving two-hour pain freedom compared to gepants. Given that gepants have established long-term quality of life benefits, Symbravo's demonstration of sustained positive effects positions it to compete effectively within this therapeutic class.
Symbravo received FDA approval in January 2025 following positive results from the MOMENTUM and INTERCEPT Phase III trials, which established its immediate efficacy in achieving headache pain freedom two hours after dosing. The current long-term data provides additional evidence supporting its clinical value proposition as a second-line treatment option in the acute migraine (搜索) market.